drugset / Trial / NCT02779348

Effect of BIA 3-202 on the Pharmacokinetics and Pharmacodynamics of Warfarin

NCT02779348

Phase 1 Completed 16 enrolled Bial - Portela C S.A.
RandomizedCrossoverOpen-labelTreatment

Summary

The purpose of this study is to determine whether multiple-dose administration of nebicapone affects the pharmacokinetics of warfarin.

Timeline

Start
2006-09
Primary completion
2006-12
Completion
2006-12

Drugs

EvaluationDrugModalityDoseRoute
Subject Nebicapone Small molecule 200 mg
Subject Warfarin Small molecule 25 mg

Indications

No indication recorded.